Advertisement

Comparison of Frequency of Atherosclerotic Cardiovascular Disease Events Among Primary and Secondary Prevention Subgroups of the Systolic Blood Pressure Intervention Trial

Published:September 06, 2019DOI:https://doi.org/10.1016/j.amjcard.2019.08.028
      The Pooled Cohort Equation (PCE) predicts 10-year risk of first-time atherosclerotic cardiovascular disease (ASCVD) events and was incorporated in analyses of a primary and secondary prevention population in the Systolic Blood Pressure Intervention Trial (SPRINT). Whether PCE enhances risk prediction among secondary prevention populations is unknown. We sought to compare ASCVD events by level of PCE-predicted risk among primary and secondary prevention SPRINT populations. SPRINT randomized adults with hypertension and ≥1 CVD risk factor or previous CVD events to systolic blood pressure control targeting <120 mm Hg or 135 to 139 mm Hg. We calculated the hazard ratio (HR) of ASCVD events among secondary versus primary (reference) prevention subgroups overall and by predicted 10-year ASCVD risk categories (<10%, 10% to <20%, 20% to <30%, and ≥30%) and within risk subgroups, comparing to the lowest risk category. Among 8,151 participants, 16% with previous CVD, mean age was 66 years and 35% were women. The HR for ASCVD events overall was 2.51 (1.96, 3.20). HR was 2.97 (1.47, 5.99) among <10% 10-year risk and 2.23 (1.38, 3.59) among ≥30% risk. Within subgroups comparing ≥30% to <10% risk (reference) categories, the HR was 2.85 (1.76, 4.63) for primary and 2.14 (1.07, 4.30) for the secondary prevention. In conclusion, history of previous events was a potent risk factor for subsequent ASCVD events. The PCE does not enhance risk prediction among secondary prevention populations and may differentially underestimate risk in secondary prevention populations with lowest predicted risk.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Goff DC
        • Lloyd-Jones DM
        • Bennett G
        • Coady S
        • D'Agostino RB
        • Gibbons R
        • Greenland P
        • Lackland DT
        • Levy D
        • O'Donnell CJ
        • Robinson JG
        • Schwartz JS
        • Shero ST
        • Smith SC
        • Sorlie P
        • Stone NJ
        • Wilson PWF
        • American College of Cardiology/American Heart Association Task Force on Practice Guidelines
        2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.
        J Am Coll Cardiol. 2014; 63: 2935-2959
        • Whelton PK
        • Carey RM
        • Aronow WS
        • Casey DE
        • Collins KJ
        • Himmelfarb CD
        • DePalma SM
        • Gidding S
        • Jamerson KA
        • Jones DW
        • MacLaughlin EJ
        • Muntner P
        • Ovbiagele B
        • Smith SC
        • Spencer CC
        • Stafford RS
        • Taler SJ
        • Thomas RJ
        • Williams KA
        • Williamson JD
        • Wright JT
        2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
        Hypertension. 2017; (HYP.0000000000000066)
        • Stone NJ
        • Robinson JG
        • Lichtenstein AH
        • Bairey Merz CN
        • Blum CB
        • Eckel RH
        • Goldberg AC
        • Gordon D
        • Levy D
        • Lloyd-Jones DM
        • McBride P
        • Schwartz JS
        • Shero ST
        • Smith SC
        • Watson K
        • Wilson PWF
        • American College of Cardiology/American Heart Association Task Force on Practice Guidelines
        2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.
        J Am Coll Cardiol. 2014; 63: 2889-2934
        • Grundy SM
        • Stone NJ
        • Bailey AL
        • Beam C
        • Birtcher KK
        • Blumenthal RS
        • Braun LT
        • Ferranti S de
        • Faiella-Tommasino J
        • Forman DE
        • Goldberg R
        • Heidenreich PA
        • Hlatky MA
        • Jones DW
        • Lloyd-Jones D
        • Lopez-Pajares N
        • Ndumele CE
        • Orringer CE
        • Peralta CA
        • Saseen JJ
        • Smith SC
        • Sperling L
        • Virani SS
        • Yeboah J
        2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
        J Am Coll Cardiol. 2019; 73: 3168-3209
        • Phillips RA
        • Xu J
        • Peterson LE
        • Arnold RM
        • Diamond JA
        • Schussheim AE
        Impact of cardiovascular risk on the relative benefit and harm of intensive treatment of hypertension.
        J Am Coll Cardiol. 2018; 71: 1601-1610
        • Plante TB
        • Juraschek SP
        • Miller ER
        • Appel LJ
        • Cushman M
        • Littenberg B
        Comparison of frequency of atherosclerotic cardiovascular and safety events with systolic blood pressure <120 mm hg versus 135-139 mm hg in a Systolic Blood Pressure Intervention Trial primary prevention subgroup.
        Am J Cardiol. 2018; 122: 1185-1190
        • SPRINT Executive Committee
        Systolic Blood Pressure Intervention Trial (SPRINT): Protocol Version 4.0.
        2012 (Available at:) (Accessed June 14, 2018)
        • Wright Jr., JT
        • Williamson JD
        • Whelton PK
        • Snyder JK
        • Sink KM
        • Rocco MV
        • Reboussin DM
        • Rahman M
        • Oparil S
        • Lewis CE
        • Kimmel PL
        • Johnson KC
        • Goff Jr., DC
        • Fine LJ
        • Cutler JA
        • Cushman WC
        • Cheung AK
        • Ambrosius WT
        • SPRINT Research Group
        A randomized trial of intensive versus standard blood-pressure control.
        N Engl J Med. 2015; 373: 2103-2116
        • Harrell FE
        Regression Modeling Strategies: With Applications to Linear Models, Logistic and Ordinal Regression, and Survival Analysis.
        Springer, Switzerland2015
        • Ridker PM
        • Buring JE
        • Rifai N
        • Cook NR
        Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score.
        JAMA. 2007; 297: 611-619
        • Ridker PM
        • Paynter NP
        • Rifai N
        • Gaziano JM
        • Cook NR
        C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men.
        Circulation. 2008; 118 (4p following 2251): 2243-2251
        • Hippisley-Cox J
        • Coupland C
        • Brindle P
        Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study.
        BMJ. 2017; 357: j2099
        • Woodward M
        • Brindle P
        • Tunstall-Pedoe H
        • SIGN group on risk estimation
        Adding social deprivation and family history to cardiovascular risk assessment: the ASSIGN score from the Scottish Heart Health Extended Cohort (SHHEC).
        Heart Br Card Soc. 2007; 93: 172-176
        • Muntner P
        • Colantonio LD
        • Cushman M
        • Goff DC
        • Howard G
        • Howard VJ
        • Kissela B
        • Levitan EB
        • Lloyd-Jones DM
        • Safford MM
        Validation of the atherosclerotic cardiovascular disease Pooled Cohort risk equations.
        JAMA. 2014; 311: 1406-1415
        • Kannel WB
        • McGee D
        • Gordon T
        A general cardiovascular risk profile: the Framingham Study.
        Am J Cardiol. 1976; 38: 46-51
        • Anderson KM
        • Wilson PW
        • Odell PM
        • Kannel WB
        An updated coronary risk profile. A statement for health professionals.
        Circulation. 1991; 83: 356-362
        • Sara JDS
        • Lennon RJ
        • Gulati R
        • Singh M
        • Holmes DR
        • Lerman LO
        • Lerman A
        Utility of the Framingham Risk score in predicting secondary events in patients following percutaneous coronary intervention: a time-trend analysis.
        Am Heart J. 2016; 172: 115-128
        • Dorresteijn JAN
        • Visseren FLJ
        • Wassink AMJ
        • Gondrie MJA
        • Steyerberg EW
        • Ridker PM
        • Cook NR
        • Graaf Y van der
        • SMART Study Group
        Development and validation of a prediction rule for recurrent vascular events based on a cohort study of patients with arterial disease: the SMART risk score.
        Heart Br Card Soc. 2013; 99: 866-872
        • Kaasenbrood L
        • Boekholdt SM
        • Graaf Y van der
        • Ray KK
        • Peters RJG
        • Kastelein JJP
        • Amarenco P
        • LaRosa JC
        • Cramer MJM
        • Westerink J
        • Kappelle LJ
        • Borst GJ de
        • Visseren FLJ
        Distribution of estimated 10-year risk of recurrent vascular events and residual risk in a secondary prevention population.
        Circulation. 2016; 134: 1419-1429